Compare JJSF & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JJSF | LBRX |
|---|---|---|
| Founded | 1971 | 2015 |
| Country | United States | United States |
| Employees | 1800 | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 1995 | 2025 |
| Metric | JJSF | LBRX |
|---|---|---|
| Price | $76.63 | $37.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $140.00 | $46.60 |
| AVG Volume (30 Days) | 148.8K | ★ 262.4K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | N/A | ★ 98.22 |
| EPS | ★ 1.99 | N/A |
| Revenue | ★ $1,022,038,000.00 | N/A |
| Revenue This Year | $0.30 | N/A |
| Revenue Next Year | $1.70 | N/A |
| P/E Ratio | $38.78 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $68.87 | $13.40 |
| 52 Week High | $99.14 | $50.16 |
| Indicator | JJSF | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 30.37 | 29.80 |
| Support Level | $72.93 | $26.75 |
| Resistance Level | $78.56 | $49.74 |
| Average True Range (ATR) | 1.87 | 2.08 |
| MACD | -0.69 | -1.10 |
| Stochastic Oscillator | 4.92 | 4.25 |
J&J Snack Foods Corp. manufactures snack foods and distributes frozen beverages, which it markets nationally to the foodservice and retail supermarket industries. The company's portfolio of frozen beverages, frozen novelties, and baked goods includes soft pretzels, frozen juice treats and desserts, stuffed sandwiches, churros, funnel cakes, cookies, and other snack foods and drinks. It operates through three segments: Food Service, which sells snacks, desserts, and baked goods at the point of sale; Retail Supermarkets, which sells frozen and prepackaged products to supermarkets; and Frozen Beverages, which sells frozen beverages under the ICEE, Slush Puppie, and Parrot Ice brands in the United States, Mexico, and Canada. The majority of revenue comes from the Food Service segment.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.